Abstract 2165: Reproducibility of a 12-gene panel and development of user-friendly nomogram-based calculator for clinical management of surgically resected non-small cell lung cancer patients

Introduction: Most NSCLC patients treated with curative approaches will experience relapses and disease progression regardless of adjuvant chemotherapy (ACT). Currently, specific criteria lack to define patients who will be benefited from ACT. Aim: To validate a 12-gene panel for predicting outcome and ACT benefit in NSCLC patients and to build a user-friendly nomogram-based calculator for estimation of survival probability. Methods: Surgically resected NSCLC patients were retrospectively selected (n=118) and tumor tissues (FFPE) were used for RNA isolation (RNeasy FFPE Mini Kit). The 12-gene panel (ATP8A1, AURKA, C1orf116, COL4A3, DOCK9, HOPX, HSD17B6, IFT57, MBIP, NKX2-1, RRM2, TTC37) was evaluated by ElementsXT (NanoString) and normalized by housekeeping genes - developed by Yang et al, 2019. The risk score was calculated (PCA-based model) and a cutoff value was set (R mclust package) to stratify patients into two groups: high-risk patients (n=59; ACT benefit) and low-risk patients (n=59; ACT non-benefit). Kaplan-Meier and Log-rank test were used for survival analysis and for evaluating prognostic performance of the 12-gene panel (all patients with no event were censored at 60 months of follow up for both overall - OS - and progression-free survival - PFS). Cox Regression model was used for the development of the nomogram model and significant variables were employed for the final model and for the user-friendly nomogram-based calculator. Results: The 12-gene panel stratified the patients (n=118) into two groups, high-risk and low-risk groups for both OS and PFS (HR=4.21; p